Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $25.04, for a total value of $25,040.00. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at $325,520. The trade was a 7.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total value of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $24,420.00.

Enliven Therapeutics Stock Down 0.9 %

NASDAQ ELVN traded down $0.21 on Tuesday, reaching $23.86. The company had a trading volume of 192,813 shares, compared to its average volume of 191,728. The stock has a market capitalization of $1.17 billion, a P/E ratio of -12.56 and a beta of 1.04. The company’s fifty day moving average is $24.91 and its 200 day moving average is $24.37. Enliven Therapeutics, Inc. has a 52-week low of $10.90 and a 52-week high of $30.03.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Enliven Therapeutics by 10.6% in the 3rd quarter. FMR LLC now owns 6,296,179 shares of the company’s stock valued at $160,804,000 after buying an additional 601,611 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after purchasing an additional 313,019 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after purchasing an additional 67,813 shares during the last quarter. State Street Corp increased its position in shares of Enliven Therapeutics by 2.9% during the 3rd quarter. State Street Corp now owns 745,944 shares of the company’s stock valued at $19,051,000 after purchasing an additional 21,018 shares during the last quarter. Finally, First Turn Management LLC increased its position in shares of Enliven Therapeutics by 29.5% during the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Robert W. Baird increased their target price on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.